Shana M. Owens
Post-Doctoral Fellow
Also affiliated: Arkansas Children's Hospital (2022)
Postdoc Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Shana M. Owens' research focuses on viral infections, particularly gammaherpesviruses and SARS-CoV-2. Her work investigates the mechanisms of virus latency and reactivation, with recent studies exploring the role of B cells and STAT3 signaling in gammaherpesvirus 68 infection in mice. This research utilized an in vivo competition model to understand B cell-intrinsic support of latency and interferon suppression. Owens has also contributed to understanding the host immune response to SARS-CoV-2, examining the development of ACE2 autoantibodies and conducting seroprevalence surveys in Arkansas. Her publications include work on the protective effects of replication-deficient gammaherpesvirus vaccines in mice, demonstrating their ability to prevent lytic disease and reduce latency establishment. Owens collaborates with researchers at the University of Arkansas for Medical Sciences, including J. Craig Forrest, Joshua L. Kennedy, Catherine Kirkpatrick, and Marianne Kouassi, with whom she shares multiple publications.
Metrics
- h-index: 7
- Publications: 27
- Citations: 366
Selected Publications
-
Repression of productive viral replication by KSHV LANA correlates with reduced adaptive immune activation: potential implications for KSHV immune evasion (2026)
-
The amplitude of gammaherpesvirus lytic replication dictates adaptive immune activation: Potential implications for KSHV LANA in immune evasion (2026)
-
Intrinsic p53 activation restricts gammaherpesvirus driven germinal center B cell expansion during latency establishment (2025)
-
A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment (2024)
-
Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models (2024)
-
Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice (2023)
-
B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model (2023)
-
Lytic Replication and Reactivation from B Cells Is Not Required for Establishing or Maintaining Gammaherpesvirus Latency <i>In Vivo</i> (2022)
-
Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas (2022)
-
Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic (2022)
-
Development of ACE2 autoantibodies after SARS-CoV-2 infection (2021)
-
Lytic Replication and Reactivation from B Cells Is Not Required for Maintaining Gammaherpesvirus Latency <i>in vivo</i> (2021)
-
Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic (2021)
-
Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas (2021)
-
Deletion of Murine Gammaherpesvirus Gene <i>M2</i> in Activation-Induced Cytidine Deaminase-Expressing B Cells Impairs Host Colonization and Viral Reactivation (2020)
Collaboration Network
Top Collaborators
- Development of ACE2 autoantibodies after SARS-CoV-2 infection
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
Showing 5 of 12 shared publications
- Development of ACE2 autoantibodies after SARS-CoV-2 infection
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic
- Temporal Variations in Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Infections by Race and Ethnicity in Arkansas
- Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas
- Pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
- Lytic Replication and Reactivation from B Cells Is Not Required for Establishing or Maintaining Gammaherpesvirus Latency <i>In Vivo</i>
- Intrinsic p53 activation restricts gammaherpesvirus driven germinal center B cell expansion during latency establishment
- Lytic Replication and Reactivation from B Cells Is Not Required for Maintaining Gammaherpesvirus Latency <i>in vivo</i>
- The amplitude of gammaherpesvirus lytic replication dictates adaptive immune activation: Potential implications for KSHV LANA in immune evasion
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
- B cell-intrinsic STAT3-mediated support of latency and interferon suppression during murine gammaherpesvirus 68 infection revealed through an <i>in vivo</i> competition model
- A replication-deficient gammaherpesvirus vaccine protects mice from lytic disease and reduces latency establishment
- Multifaceted roles for STAT3 in gammaherpesvirus latency revealed through <i>in vivo</i> B cell knockout models
- Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice
Similar Researchers
Based on overlapping research topics